10/05/2026
DIABETES UPDATES
Awiqli (insulin icodec-abae) is a groundbreaking, once-weekly long-acting basal insulin approved in March 2026 for treating adults with type 2 diabetes. Developed by Novo Nordisk, it replaces daily basal injections by providing steady blood sugar control over 7 days, reducing the burden of treatment.
Key Details for Awiqli InsulinAdministration: It is a subcutaneous, once-weekly injection using a prefilled FlexTouch pen.
Approval Status: Approved in the US, Canada, and by the EMA.
Mechanism: As an ultra-long-acting analog, it binds to albumin for a slow, continuous release over seven days.
Safety & Efficacy: Clinical trials (ONWARDS) show effectiveness comparable to daily insulins, with hypoglycemia as the most common side effect.
Storage: Unopened pens are refrigerated 2C to 8C while in-use pens last up to 12 weeks at room temperature up to 30 C